Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

Koji Sasaki, Jason R. Gotlib, Ruben A. Mesa, Kate J. Newberry, Farhad Ravandi, Jorge E. Cortes, Patrick Kelly, Jeffery L. Kutok, Hagop M. Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Fingerprint Dive into the research topics of 'Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis'. Together they form a unique fingerprint.

Medicine & Life Sciences